2023 Meeting Magazine - 35

For adults with active psoriatic arthritis (PsA)1
#1 PRESCRIPTION ANALYSIS
CALCULATED BY COMBINED
PRESCRIPTION DATA ACROSS
Ps AND PsA
PRESCRIBED BIOLOGIC
BY DERMATOLOGISTS FOR PATIENTS
WITH PSORIATIC DISEASE
For patients with psoriatic disease, defined as
those with plaque psoriasis or psoriatic arthritis.
Source of data: Integrated Symphony Health
(PatientSource) as of 8/2022.2
NOTHING IS
EVERYTHING
Nothing less than the opportunity
to reach for their treatment goals
WELL-STUDIED
SAFETY PROFILE
Evaluated in 24 clinical trials (4 PsA, 20 Ps)3
*
Up to ~8 years of safety data in Ps, ~3 years
in PsA3
The safety profi le in PsA is generally
consistent with the safety profi le of patients
with Ps (PsA Week 24, Ps Week 16)1
&
For your PsA patients,
that's everything.
EFFICACY IN PsA
DOMAINS
Robust Joint Effi cacy: SKYRIZI met its primary
endpoint (ACR20 at Week 24) in 2 clinical trials.
ACR50/70, complete resolution of enthesitis/
dactylitis, and minimal disease activity were
achieved at Week 24. Response rates observed up
to ~2 years in PsA.1,4-6
Durable Skin Clearance: PASI 90 response was
achieved at Week 24. Response rates observed up
to ~2 years.4-6
EXCEPTIONAL ACCESS
& SUPPORT
>95% of commercial and Medicare Part D patients
have preferred†
fi rst-line TIM coverage with no
requirements of a prior biologic.7‡
National commercial and Medicare Part D formulary coverage under
the pharmacy benefi t as of February 2023.
Skyrizi Complete provides exceptional 1:1
patient support.
STUDY DESIGNS1
KEEPsAKE 1: Week 24, randomized, double-blind, placebo-controlled study of 964 csDMARD-IR adult patients with active PsA. KEEPsAKE 2: Week 24, randomized, double-blind,
placebo-controlled study of 443 mixed population (~50% csDMARD-IR, ~50% Bio-IR) adult patients with active PsA.
INDICATIONS1
Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic
arthritis in adults.
Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to
severe plaque psoriasis in adults who are candidates for systemic therapy
or phototherapy.
*Includes 4 PsA Phase 2-3 studies (including KEEPsAKE 1 and KEEPsAKE 2). Includes 20 Phase 1-4 studies
in Ps encompassing 5 trials using integrated data evaluated at Week 16 (including UltIMMa-1, UltIMMa-2,
IMMhance, and IMMvent) and 15 additional trials, including LIMMitless.3
†SKYRIZI is on a preferred tier or otherwise has preferred status on the plan's formulary.
‡
Coverage requirements and benefit designs vary by payer and may change over time. Please consult with
payers directly for the most current reimbursement policies.
ACR=American College of Rheumatology; ACR20/50/70=≥20/50/70% improvement in
American College of Rheumatology score; PASI 90=≥90% reduction in Psoriasis Area and
Severity Index; Ps=psoriasis; PsA=psoriatic arthritis; TIM=targeted immunomodulator.
SAFETY CONSIDERATIONS1
SKYRIZI is contraindicated in patients with a history of serious
hypersensitivity reaction to risankizumab-rzaa or any of its excipients.
Serious hypersensitivity reactions, including anaphylaxis, have been
reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs,
discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI
may increase the risk of infection. Instruct patients to report signs or
symptoms of clinically important infection during treatment. Should such
an infection occur, discontinue SKYRIZI until infection resolves. Evaluate
patients for tuberculosis infection prior to initiating treatment with SKYRIZI.
Avoid use of live vaccines in SKYRIZI patients.
Please see additional Important Safety Information on the next page.
Please see the Brief Summary of full Prescribing Information on the
adjacent page.

http://www.SkyriziHCP.com/rheumatology

2023 Meeting Magazine

Table of Contents for the Digital Edition of 2023 Meeting Magazine